Imbrium Therapeutics L.P., a subsidiary of Purdue Pharma L.P. (“Purdue”), has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to evaluate sunobinop for the potential treatment of moderate to severe alcohol use disorder (AUD)*.

Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest research, Treatment with shRNA

Ocugen, Inc., a biotechnology company specializing in gene and cell therapies and vaccines, has received FDA approval for its expanded access program (EAP) for adult patients aged 18 and older with retinitis pigmentosa (RP) to access OCU400, a gene therapy candidate.

The U.S. Food and Drug Administration has approved Tecelra for the treatment of adults with unresectable or metastatic synovial sarcoma who have previously received chemotherapy

Jade Biosciences, Inc., a biotech company focused on innovative treatments for autoimmune diseases, has announced the successful completion of an $80 million financing round. This round was led by Fairmount and Venrock Healthcare Capital Partners

Celltrion Healthcare Canada Limited has announced that Steqeyma® (ustekinumab injection) and Steqeyma® I.V. (ustekinumab for injection, solution for intravenous infusion) have been approved by Health Canada.

Kexing Biopharm has secured approval from the European Commission for Apexelsin®, a generic alternative to Abraxane® (nab-paclitaxel) by Bristol Myers Squibb and Celgene. WhiteOak Pharmaceutical B.V. developed Apexelsin®

Alcyone Therapeutics Inc., a biotechnology company specializing in advanced genetic therapies and delivery systems for complex neurological conditions, has announced that the U.S. Food and Drug Administration

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved DARZALEX FASPRO® in combination with bortezomib, lenalidomide, and dexamethasone for use as induction

Georgiamune Inc., a biotechnology company in its clinical stages, has announced the initiation of a Phase 1 trial involving their new drug, GIM-531. This study marks the first human dosing of GIM-531, an oral therapy